Back

Integrating EPA based therapy in the management of residual risk.

29 August 2021 (11:50 - 12:00)
Organised by:
Congress Presentation Part of: Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Open Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Professor Philippe Gabriel Steg

Hospital Bichat-Claude Bernard, Paris (France)

2 More presentations in this session

Presentation thumbnail
Unravelling the triglycerides story: Lessons from genetics and clinical trials.
Professor P. Libby (Boston, US)
Video
Presentation thumbnail
EPA based therapy in CAD: What do we know?
Professor L. Tokgozoglu (Ankara, TR)
Video

Access the full session

Session thumbnail
Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides
Video

The Event

Event poster

ESC Congress 2021 - The Digital Experience

29 August 2021 11:50 CET
You may be interested in
thumbnail
Webinar
Update on dyslipidaemia management: focus on risk estimation and lipoprotein(a)
7 October 2025
thumbnail
Congress Presentation
Icosapent ethyl in clinical practice: the Spanish experience
29 August 2025
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
19 July 2023
thumbnail
Congress Presentation
How to make the best treatment decisions for the individual patient with pulmonary arterial hypertension
26 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources